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worsened during the periods free of infiltrates. He became CS-Organizing Pneumonia (OP) is classified as an Idiopathic
Interstitial Pneumonia (IIP).1 Clinically, the patients present
dyspnea, cough, and low fever, and usually respond well to
corticosteroids, reaching clinical and radiologic resolution in
a short timeframe. However, sometimes infiltrates do recur
and may not resolve. Radiologically, migratory consolida-
tions are identified in high-resolution computed tomography
(HRCT), sometimes associated with progressive fibrosis with
reticulation and areas of persistent consolidation.1 The his-
tology reveals “proliferation of fibroblastic tissue within small
airways, alveolar ducts, and alveolar spaces”.2 OP can be
secondary to other pathologies such as common variable
immunodeficiency3 and malignant disease among others.4
At times no etiology is identified and the term Cryptogenic
Organizing Pneumonia (COP) is used.1 Furthermore, OP could
coexist or mimic  a malignant disease.4,5
We  present a case of a 56-year-old (y/o) man, ex-smoker
of 19 pack-years, an engineer without any contact with
chemical products. He lived in a flat without detectable expo-
sures, and indicated no alcohol or drug abuse. In 2002 (41
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open  access article under the CC BY-NC-ND license (http://creativecomy/o), he was monitored by other center due to dispnea,
non-productive cough and low-grade fever. There were no
remarkable indicators during physical examination (no patho-
logical breathing sounds, 98% oxygen saturation at room
air). Laboratory studies highlighted neutrophil-predominant
leukocytosis and elevated level of C-reactive protein. X-ray
findings and High-Resolution Computed Tomography (HRCT)
showed lung infiltrates that migrated from one relapse to the
other. We do not dispose from other data (bronchoalveolar
lavage. . .). Initially, the clinical situation and infiltrates had
complete remission with 15 mg per day of corticosteroids (CS).
He remained asymptomatic for a long period of time (several
months to a year). However, the time he remained free of infil-
trates shortened and required increasing doses of cortisone
up to 30 mg  per day. Subsequently the patient could not dis-
continue corticosteroid use because his respiratory conditionersity Hospital, c/FeixaLlarga S/N, L’Hospitalet, 08907, Barcelona,
resistant in 2011 requiring 15 mg  per day minimum. During
this time, he required hospitalization for some of the recur-
rences (2002, 2004(x2), 2008, 2011). For every hospitalization,












































hematol transfus cell th
e had migrating chest infiltrates and neutrophilic leuko-
ytosis without any evidence of infection. An open surgical
ung biopsy was performed by videothoracoscopy (VATS) in
rder to confirm a diagnosis in April 2013 under 25 mg/day
f prednisone. Anatomic pathological findings were described
s septal thickening and paraseptal fibrosis without fibrob-
ast foci (FF). The case was then referred to our center, under
rescription of CS and azathioprine. Azathioprine was quickly
emoved because of gastric intolerance.
During the first visit at our center in August of 2013, a
ew infiltrate at the upper right lobe with mediastinal lymph
odes was detected and it increased progressively through
ne year of follow-up. Our anatomopathologist (Dr. Llatjos)
eviewed the previous lung biopsy and agreed with the clinical
escription of unspecific fibrosis without FF, however no spe-
ific diagnosis could be done. Patient declined another surgical
ung biopsy or cryobiopsy. A Bronchoalveolar Lavage (BAL),
T-Guided Tru-Cut (Fig. 1A and B) and an EBUS were per-
ormed. BAL showed a dominance of macrophages. Lung and
denopathy cytologies showed lymphocytic infiltrates with-
ut, atypia nor lymphoma markers and with negative cultures.
he patient required high doses of CS (prednisone 40 mg  per
ay) at this time. In order to diminish the side effects of pred-
isone, mycophenolate mofetil (MMF)  was initiated but it was
iscontinued after 6 months due to no clinical improvement.
everal laboratory studies (proteinogram, lymphocyte subsets,
ormones, autoimmunity, antibodies, and precipitins, among
thers) and urine analyses (ions, proteins and globulins
xcretion) were performed searching for other causes. Only
ypogammaglobulinemia was detected (Immunoglobulin G
38 mg/dL and Immunoglobulin A 41 mg/dL) without markers
f hematological, oncological or autoimmune disease. Then
mmunoglobulin replacement therapy3 was dispensed for a
ear, but was ceased due to lack of clinical improvement.
ulmonary function tests reflected a progressive restrictive
attern of decreasing forced vital capacity (FVC) from 2013 to
016 (from 3,330 L [77% of the predicted value] to 2,150 L [56,7%
ig. 1 – CT-Guided Tru-Cut. A) interstitial fibrosis with mainly pe
) mild interstitial chronic inflammation. Lymphocytic infiltrates
hese samples. Cryobiopsy in right upper lobe. C) mild interstitia
alignancy were  observed, either lymphoid or epithelial. D) pulm
rchitecture in one of three fragments. Elastosis and amyloidosis 0 2 0;4 2(2):176–179 177
of the predicted value]) and a gradual decrease in diffusing
lung capacity for carbon monoxide (DLCO) from 71% to 56.1%.
In February of 2016, a new infiltrate in the right basal
lobe appeared with enlargement of lymph nodes. Cryobiop-
sies (performed in August, September and November of 2016)
(Fig. 1C and D) from the upper and basal right lobes revealed
collagen, elastin and lymphocytes without cellular atypia.
Another EBUS was performed (January of 2017) and again
revealed no cellular atypia or lymphoma markers. Labora-
tory analysis showed elevation of Plasmatic 2-microglobulin,
plasmatic lambda chains and urine monoclonal kappa light
chains. Bone marrow and subcutaneous fat aspiration were
performed without finding any structural, cytological or
haematological alteration. Then, biopsies (open lung biopsy
(2013) and criobiopsies (2016)) were re-evaluated by another
expert anathomopathologist from the Instituto Nacional de
Enfermedades Respiratorias (INER, México; Dr. Gaxiola) who
coincide with the description of our anathomopathologist and
could not give a specific diagnosis either. Furthermore, the
case was exposed to the CRAMPID goup (Clinical-Radiological-
Anathomopathological ILD group from Catalunya) and expert
ILD-radiologists defended fibrosing OP as the radiologic diag-
nose (Dr. Franquet, Dr. Luburich). The patient needed several
hospitalizations because of respiratory insufficiency requiring
elevated doses of corticosteroids. A PET/CT was performed at
the end of 2017, exhibiting hypermetabolical lesions in lung,
mediastinal lymph nodes and a nodular centimetric lesion
adhered to psoas.
Biopsy of the psoas lesion was compatible with a high-
grade diffuse large B-cell lymphoma (DLBCL). Rituximab was
initiated in monotheraphy due to comorbidities and Eastern
Cooperative Oncology Group (ECOG) status. After the third
dose, the patient died due to a Pseudomonas sepsis caused
by severe neutropenia. Necropsy revealed DLBCL (Fig. 2A–D)
affecting the retroperitoneum and right lung, with adjacent
OP and diffuse alveolar damage. Classical Hodgkin lymphoma
(HL) was evidenced in the mediastinal lymph nodes (Fig. 2E–H).
ribronchiolar distribution, but no fibroblastic foci observed.
 without atypia. No intraluminal organizing fibrosis in
l chronic inflammation. No atypical cells suspicious for
onary fibrosis with complete remodeling of lung
 were ruled out.
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Fig. 2 – Autopsy: Right lung with Diffuse Large B-Cell Lymphoma (DLBCL). A transverse section of the right lung showing a
3.8 cm solid and cream colored nodule (arrow). B Lung parenchyma with presence of DLBCL (arrow) (H-E 40×). C Proliferation
of large lymphocytes (H-E 400×). D Immunohistochemical stained for CD20 that demonstrates the B lineage of proliferation
(40×).
Mediastinal lymph node with Classic Hodgkin Lymphoma. E Mediastinal adenopathy of 5.5 cm.  F Hodgkin cells in a cellular
background rich in lymphocytes and containing histiocytes (H-E 400×). G Immunohistochemical staining for CD3 (200×). H
r
Immunohistochemical staining for CD30 (200×).
In this case, two different forms of aggressive lymphoma
(DLBCL and HL) coexisted in the necropsy, which is very
unusual.6–8 Although there had been extensive investigations,
the appearance of malignancy 4 years before death could
not be proven. The diagnosis of lymphoma simultaneously
with OP has already been described4,5; however, there is no
evidence of association of OP before aggressive lymphoma
detection, and in this case there is not evidence of hematologic
malignant transformation.6–8 This case never demonstrated
histological evidence of OP alive (only in the necropsy). This
opens the case to the discussion of several questions.
The first question is whether the lymphoma could have
been present in the lung for years, but modulated by the con-
tinuous steroid use. The diagnosis of the lung lymphoma was
Hodgkin’s lymphoma, which didn’t respond to years of steroid
use. Only low-grade lymphomas (marginal zone, small lym-
phocytic lymphomas) respond to steroids, and only for a short
period of time.
Another issue to consider is whether the lymphomas
could have resulted from continuous immunosuppres-
sion. Hodgkin’s lymphoma and EVB negative DLBL are not
usually associated with immunosuppression. The clas-
sical lymphomas associated with immunosuppressive
treatment9/solid organ transplant10 are usually EVB-related
with an aggressive clinical presentation if they are not treated.
However, EBV was negative in our patient and he received
only 6 months of MMF  at the time when the infiltrate was
already persistent.
An additional question is whether a repeated open chest
biopsy, refused by the patient, could have led to an earlier lym-
phoma diagnosis. Unfortunately, the patient rejected it several
times, as he had already undergone multiple lung biopsies
(cryobiopsy and EBUS) in the endeavor to diagnose this young
patient.Another inquiry is whether all sites of increased
metabolism in PET, including mediastinal nodes and lung,
should have been explored. Usually, all sites PET positive in
lymphoma patients are not biopsied assuming that all sites are
going to be the same lymphoma subtype. In this patient, psoas
biopsy was more  accessible than the other localizations, and
gave the diagnosis of DLBCL. The other sites we  considered
the same histology, and therefore unexpected in the necropsy
to find Hodgkin’s lymphoma in the lung.
The last question is to determine whether rituximab, as
the only treatment, was the right choice at that juncture for
the treatment of DLBCL. When the diagnosis was made (only
Diffuse large B cell lymphoma, Hodgkin’s lymphomas diagno-
sis was elucidated in the necropsy), the patient had a poor
ECOG with an active infection, so the hematology department
decided to administer only Rituximab to avoid neutropenia, a
spread of the infection.
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